← Home

ILA

Healthcare & BiotechCOILED

$0.450

as of 2026-09-09

5d return

+2.3%

20d return

-2.2%

60d return

+21.6%

RSI 14

47.2

vs 52w high

-21.1%

vs 52w low

+52.5%

SMA 20

Below

SMA 50

Above

Price · Volume · Broker flow
Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike.
Loading chart…
Closest correlates
Pearson r on log returns, window: 82d
  • HMGr=0.58, window: 82d
  • RCLr=0.34, window: 82d
  • APCr=0.29, window: 82d
  • 14Dr=0.29, window: 82d
  • DTIr=0.28, window: 82d
Announcements — last 30 days
  • 2026-08-31PSotherPivotal Marburg data secured for Galidesivir FDA pathway

    ILA has secured FDA-critical natural history data for Marburg via a six-month negotiation, eliminating need to replicate expensive BSL-4 work and unlocking the Animal Rule pathway. Two coordinated NHP efficacy studies (USAMRIID next quarter, Texas Biomed Q1 2027) now have a regulatory foundation, but approval remains 2+ years away and capital adequacy is tight at $12.9m against current burn.

  • 2026-08-21PSotherIsland boosts Galidesivir supply as Ebola surges

    Island is executing a deliberate biodefence strategy by securing a substantial GMP-grade Galidesivir inventory (700–800 courses by Q4 2026) ahead of active deployment in Uganda, where the rapidly accelerating Bundibugyo Ebola outbreak (5,208 cases, 47.5% CFR) creates both an urgent need and a human data generation opportunity. The move reduces the company's manufacturing cycle dependency and positions it for government/biodefence agency engagement without waiting for pivotal trial data.